54.68
price down icon2.44%   -1.37
after-market アフターアワーズ: 55.00 0.32 +0.59%
loading
前日終値:
$56.05
開ける:
$56.32
24時間の取引高:
2.62M
Relative Volume:
1.01
時価総額:
$10.58B
収益:
$3.29B
当期純損益:
$268.74M
株価収益率:
39.90
EPS:
1.3704
ネットキャッシュフロー:
$759.12M
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
-15.53%
6か月 パフォーマンス:
+1.07%
1年 パフォーマンス:
+3.27%
1日の値動き範囲:
Value
$54.44
$56.53
1週間の範囲:
Value
$53.93
$57.59
52週間の値動き範囲:
Value
$49.26
$70.98

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1052)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,221
Name
Twitter
Name
次回の収益日
2026-10-26
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

Compare BMRN vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BMRN icon
BMRN
Biomarin Pharmaceutical Inc
54.68 10.58B 3.29B 268.74M 759.12M 1.3704
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-15 再開されました UBS Buy
2026-10-12 アップグレード Raymond James Outperform → Strong Buy
2026-08-19 開始されました BMO Capital Markets Outperform
2026-05-19 開始されました Citigroup Buy
2026-05-11 再開されました Goldman Neutral
2026-04-27 再開されました Morgan Stanley Overweight
2026-01-28 再開されました Barclays Overweight
2026-01-20 アップグレード Canaccord Genuity Hold → Buy
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
Oct 12, 2026

Raymond James upgrades BioMarin stock to strong buy on valuation - Investing.com

Oct 12, 2026
pulisher
Oct 12, 2026

Why is BioMarin Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada

Oct 12, 2026
pulisher
Oct 12, 2026

Raymond James upgrades BioMarin stock to strong buy on valuation By Investing.com - Investing.com South Africa

Oct 12, 2026
pulisher
Oct 10, 2026

Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 10, 2026
pulisher
Oct 09, 2026

RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 09, 2026
pulisher
Oct 09, 2026

BioMarin to present data on achondroplasia treatment at ASBMR - Investing.com

Oct 09, 2026
pulisher
Oct 09, 2026

New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. - Stock Titan

Oct 09, 2026
pulisher
Oct 08, 2026

BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention? - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 08, 2026
pulisher
Oct 08, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance

Oct 08, 2026
pulisher
Oct 07, 2026

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research

Oct 07, 2026
pulisher
Oct 07, 2026

RBC Capital lowers BioMarin price target to $62 - scanx.trade

Oct 07, 2026
pulisher
Oct 07, 2026

Citigroup raises BioMarin price target to $76 - scanx.trade

Oct 07, 2026
pulisher
Oct 05, 2026

BioMarin names Cara Bauer as chief people officer - Investing.com

Oct 05, 2026
pulisher
Oct 05, 2026

BioMarin Appoints Cara Bauer as Chief People Officer - PR Newswire

Oct 05, 2026
pulisher
Oct 02, 2026

BioMarin presents five-year data on Pompe disease treatment - Investing.com

Oct 02, 2026
pulisher
Oct 02, 2026

BioMarin presents five-year data on Pompe disease treatment By Investing.com - Investing.com Canada

Oct 02, 2026
pulisher
Oct 02, 2026

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress - PR Newswire

Oct 02, 2026
pulisher
Oct 02, 2026

BioMarin Pharmaceutical (NasdaqGS:BMRN) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 02, 2026
pulisher
Oct 01, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Oct 01, 2026

Profluent and BioMarin Partner to Design Novel Enzyme Therapies Using AI - HLTH

Oct 01, 2026
pulisher
Oct 01, 2026

After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. - Stock Titan

Oct 01, 2026
pulisher
Oct 01, 2026

The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

BioMarin and Profluent partner on AI-designed enzyme therapies - Pharmaceutical Technology

Oct 01, 2026
pulisher
Sep 30, 2026

Major North Bay biotech employer to cut 119 jobs in consolidation move - The Press Democrat

Sep 30, 2026
pulisher
Sep 30, 2026

Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 - TradingView

Sep 30, 2026
pulisher
Sep 30, 2026

BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 - TradingView

Sep 30, 2026
pulisher
Sep 30, 2026

Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI - marketscreener.com

Sep 30, 2026
pulisher
Sep 30, 2026

Profluent Partners With BioMarin to Design Novel Medicines Using AI - Yahoo Finance

Sep 30, 2026
pulisher
Sep 30, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts - au.finance.yahoo.com

Sep 30, 2026
pulisher
Sep 25, 2026

Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.

Sep 25, 2026
pulisher
Sep 22, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 22, 2026
pulisher
Sep 22, 2026

BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance UK

Sep 22, 2026
pulisher
Sep 22, 2026

BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Singapore

Sep 22, 2026
pulisher
Sep 22, 2026

BioMarin Pharmaceutical Inc. (BMRN) Latest Stock News & Headlines - Yahoo Finance

Sep 22, 2026
pulisher
Sep 21, 2026

BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha

Sep 21, 2026
pulisher
Sep 21, 2026

BioMarin Pharmaceutical Inc. (BMRN): Stock Analysis Reveals 43% Potential Upside - DirectorsTalk Interviews

Sep 21, 2026
pulisher
Sep 19, 2026

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - Yahoo Finance

Sep 19, 2026
pulisher
Sep 19, 2026

Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative? - Yahoo Finance

Sep 19, 2026
pulisher
Sep 18, 2026

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone - Yahoo Finance

Sep 18, 2026
pulisher
Sep 16, 2026

BioMarin Stops Voxzogo Development for Noonan Syndrome - Yahoo Finance

Sep 16, 2026
pulisher
Sep 14, 2026

BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - PR Newswire

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board - TradingView

Sep 14, 2026
pulisher
Sep 12, 2026

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance

Sep 12, 2026
pulisher
Sep 10, 2026

BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com India

Sep 10, 2026
pulisher
Sep 10, 2026

BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada

Sep 10, 2026

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Biomarin Pharmaceutical Inc (BMRN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Davis George Eric
Officer
Sep 02 '26
Proposed Sale
66.28
17,557
1,163,756
0
Friberg Gregory R
EVP, Chief R&D Officer
May 07 '26
Sale
53.85
3,281
176,682
51,818
Friberg Gregory R
Officer
May 07 '26
Proposed Sale
53.85
3,281
176,682
0
Guyer Charles Greg
EVP, Chief Technical Officer
Mar 11 '26
Sale
60.46
16,486
996,744
79,953
Guyer Charles Greg
Officer
Mar 11 '26
Proposed Sale
60.46
16,486
996,749
0
Friberg Gregory R
EVP, Chief R&D Officer
Feb 26 '26
Sale
60.38
6,326
381,937
37,578
Davis George Eric
EVP, Chief Legal Officer
Feb 26 '26
Sale
61.36
26,061
1,599,103
72,453
Friberg Gregory R
Officer
Feb 26 '26
Proposed Sale
60.38
6,326
381,937
0
Davis George Eric
Officer
Feb 26 '26
Proposed Sale
61.36
26,061
1,599,103
0
$449.74
price down icon 2.19%
$63.62
price down icon 2.53%
$72.57
price up icon 0.07%
$9.18
price down icon 8.20%
$14.63
price down icon 4.81%
$316.58
price down icon 4.07%
大文字化:     |  ボリューム (24 時間):